Pharmaceutical Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X

Q&A with Genocea: improving cancer treatment with precise, personalised targets

Genocea’s ATLAS platform can determine the best target for each individual cancer patient, primarily by identifying and excluding a new type of antigen, called an Inhibigen, which can undermine a therapy’s anti-tumour effect. Allie Nawrat talks to Genocea’s CEO and president Chip Clark about the company’s approach and how it improves on existing immune-focused approaches in oncology.


Go Top